Physician profile
Wendy Shields
NPI 1962913335
$959.58
in general payments reported to CMS, 2019-2025
20 companies · $101 in 2025
The $101 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $114 · 2022: $431 · 2023: $82.83 · 2024: $231 · 2025: $101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $375 · Long Term Medical Supply Or Device Loan: $39.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $375.31 |
| Long Term Medical Supply Or Device Loan | $39.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $201.46 | 2022-2025 | Freestyle Libre 3, Freestyle Insulinx |
| Alkermes, INC. | $167.84 | 2021-2025 | Vivitrol, Vivitrol |
| Boston Scientific Corporation | $96.92 | 2022 | |
| Janssen Pharmaceuticals, INC | $58.92 | 2021-2025 | Spravato |
| Corium, LLC | $55.77 | 2022-2025 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $55.21 | 2021-2024 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $51.94 | 2022-2024 | Rexulti, Abilify Asimtufii |
| Hologic Sales and Service, LLC | $35.38 | 2021-2024 | Aptima, Thinprep 2000 Processor |
| Takeda Pharmaceuticals U.S.A., INC. | $33.21 | 2021 | |
| Neurocrine Biosciences, INC. | $32.83 | 2022 | |
| Vanda Pharmaceuticals INC. | $21.61 | 2024 | Hetlioz, Fanapt |
| Sunovion Pharmaceuticals INC. | $20.39 | 2022 | |
| Axsome Therapeutics, INC. | $20.28 | 2024 | Auvelity |
| Gilead Sciences, INC. | $19.03 | 2023 | |
| Medtronic, INC. | $17.96 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $16.36 | 2025 | Uzedy |
| Indivior INC. | $15.52 | 2022 | |
| Ironshore Pharmaceuticals INC. | $14.72 | 2023 | Jornay Pm |
| Lundbeck LLC | $12.27 | 2022 | |
| Lilly USA, LLC | $11.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wendy Shields listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.